FundsIndia research note about Natco Pharma.
Report is very concise, which I like, however it do not mention revlimid at all.
Market is Certain that revenue will drop after revlimid patent expiry. With New projects, if company able to maintain revenue, it may see P/E expansion.
Interesting time ahead!
Heads I win big and tales I do not lose much situation.
Natco FundsIndia.pdf (1.7 MB)
D: Invested
| Subscribe To Our Free Newsletter |
